Real-time funding, M&A, exec moves & hiring — the signals that move deals
The intelligence a $25K terminal charges for — the day it breaks, in your market, at a fraction of the price.
Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.
AbCellera Biologics Inc.
AI Executive Summary
AI-powered analysis of 8-K filing content
AbCellera Biologics appointed two new Class III directors, John S. Montalbano and Stephen R. Quake, at its June 11, 2026 Annual Meeting of Shareholders. Both will serve three-year terms expiring in 2029, strengthening the company's board composition in the biotechnology sector.
Key Takeaways
John S. Montalbano (CFA) and Stephen R. Quake (D.Phil.) were elected as Class III directors at the Annual Meeting of Shareholders on June 11, 2026
Both directors will serve three-year terms expiring at the 2029 annual shareholder meeting
1 more takeaway
Related Filings (3)
3 more filings from AbCellera Biologics Inc. in the last 90 days